SEC Form 4 · accession 0001209191-19-001993
Mersana Therapeutics, Inc. · MRSN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David M Mott
Director · 10% Owner
Period of report
Jan 2, 2019
Accepted (ET)
Jan 4, 2019 · 4:34 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001442836
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $4.31 | Jan 2, 2019 | A | 25,292 | A | — | Jan 2, 2029 | Common Stock | 25,292 | 25,292 | D |
Explanation of responses
- F1The option becomes exercisable in equal quarterly installments on the last day of each calendar quarter of 2019.